Centessa Pharmaceuticals PLC
CNTA
Health Care
2
exclusion reasons
1 theme
Centessa Pharmaceuticals PLC is screened out under 2 exclusion reasons spanning 1 issue category.
This page is part of our public exclusion list — a transparency tool that shows which companies we screen out and why. It is not investment advice, and it is not an accusation. It is a statement of values.
Centessa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company whose drug development pipeline relies on animal testing. The company’s lead investigational candidates, including serpinPC for hemophilia and LB101 for solid tumors, are in clinical trials following preclinical studies conducted in animal models. This use of animals in research is a standard, integral part of the company’s business model for bringing new therapeutics to market.
The provided evidence searches returned only generic regulatory risk disclosures from SEC filings, with no specific details on the nature or scale of Centessa’s animal testing activities. This lack of specific evidence, while not negating the inherent animal exploitation in pharmaceutical R&D, means the narrative cannot detail study types, species used, or animal numbers. The exclusion is based on the company's operational category as a drug developer, where animal testing is a foundational, non-optional component of the preclinical research process.
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company whose business model depends on animal testing as a standard component of preclinical drug development. The company’s SEC filings explicitly identify “animal studies” as part of its research pathway and cite “failure to access or a significant delay in accessing animal research” as a material risk to its operations. As a developer of novel therapeutics, Centessa’s preclinical testing necessarily involves animal models to assess the safety and efficacy of its product candidates before advancing to human trials. This reliance on animal testing is inherent to its business and is commissioned or funded directly by the company.
Research Sources
5 organizations
Related Exclusions
Wondering what we do invest in?
The Naughty List
A digest of changes to our exclusion list — new additions, removals, and the evidence behind them. We review the list continuously as new evidence surfaces.
Companies appear on our exclusion list based on our investment judgment — not because they've done anything illegal. This is a difference of values and opinion, not an accusation of wrongdoing. Exclusion does not constitute a recommendation against investing in any company, and absence from the list does not constitute a recommendation to invest.
This information is provided for educational and transparency purposes only and should not be relied upon as investment advice. Data is drawn from independent watchdogs, NGOs, government registries, and Ethical Capital's ongoing research — see Research Sources for the full list.
Ethical Capital LLC is a state-registered investment adviser in Utah (CRD #316032). Registration does not imply a certain level of skill or training.